BridgeBio Reveals Interim Abstract of Phase 1 Clinical Trial Results for 4th Generation Targeted Cancer Drug 'BBT-176'

[Asia Economy Reporter Chunhee Lee] Bridge Biotherapeutics announced on the 13th that the abstract related to the interim results of the Phase 1 clinical trial of 'BBT-176,' a 4th-generation targeted lung cancer treatment under development, scheduled to be presented at the 2022 International Association for the Study of Lung Cancer World Conference on Lung Cancer (IASLC 2022 WCLC) in Vienna, Austria next month, has been released on the IASLC website on the 12th (local time).

BBT-176 is a targeted anticancer drug being developed as a 4th-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). On the 8th of next month, Professor Sunmin Lim from Yonsei Cancer Hospital Lung Cancer Center is expected to deliver an oral presentation at the World Conference on Lung Cancer, sharing the interim analysis results of the Phase 1 clinical trial involving patients with advanced non-small cell lung cancer who have shown resistance to existing treatments such as 3rd-generation EGFR inhibitors. In particular, the analysis will include antitumor activity and treatment-related adverse events in patients exhibiting triple mutations (Del19/T790M/C797S; DTC), including the C797S mutation associated with resistance to 3rd-generation EGFR inhibitors.

According to the released abstract, the interim data analysis of the Phase 1 trial confirmed tumor reduction effects of up to 30.3% compared to baseline in patients administered 320 mg of BBT-176 once daily, and up to 26.3% in patients administered 480 mg. The company plans to determine the recommended dose for the Phase 2 clinical trial by comprehensively evaluating tolerability, safety, and antitumor activity explored in Phase 1.

Jungkyu Lee, CEO of Bridge Biotherapeutics, said, “We are honored to present the interim clinical data of BBT-176 for the first time to lung cancer experts worldwide,” adding, “We will do our best to offer the first treatment option with a 4th-generation EGFR inhibitor for terminal resistant patients who have no other treatment options.” Professor Sunmin Lim also stated, “This is a hopeful result for patients who had no options after 3rd-generation targeted therapies.”